Research Journal of Pharmaceutical Dosage Form and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

A Review on HPLC Method Development and Validation for Gliptin Class: New Oral Antidiabetic Agents


Affiliations
1 PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune-412105, Maharashtra,, India
     

   Subscribe/Renew Journal


Gliptin is the class of antidiabetic medicine also called as dipeptidylpeptidase-4. DPP-4 (dipeptidyl peptidase-4) inhibitors (or "gliptins") represent a class of oral anti-hyperglycaemic agents that inhibit the enzyme DPP-4, thus augmenting the biological activity of the "incretin" hormones (glucagon-like peptide-1 [GLP-1] and glucose dependent insulinotropic polypeptide [GIP]) Sitagliptin, Saxagliptin, Alogliptin, Linagliptin, Vildagliptin are the Gliptin class inhibitor for the treatment of type 2 diabetes mellitus and they decrease the breakdown of the incretin hormones such as glucagon like peptide 1 (GLP-1). All together gliptins have a good oral bioavailability which is not significantly influenced by food intake. PK/pharmacodynamics characteristics, that is, sufficiently prolonged half-life and sustained DPP-4 enzyme inactivation, generally allow one single oral administration per day for the management of T2DM; the only exception is vildagliptin for which a twice-daily administration is recommended because of a shorter half-life DPP-4. This paper is an updated review, providing an analysis of both the similarities and differences between the various compounds known as gliptins, currently used in the clinic (sitagliptin, saxagliptin, alogliptin linagliptin and vildagliptin). This paper discusses the pharmacokinetic and pharmacodynamic characteristics of gliptins. In this review we complied analytical method development and determination of the Gliptin inhibitors. Table no.1, 2, 3, 4, 5, shows the analytical method development and validation of Sitagliptin, Saxagliptin, Alogliptin, Linagliptin, and Vildagliptin alone and with its combination by the HPCL method.

Keywords

Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, vildagliptin, Pharmacokinetic parameter, pharmacodynamics parameter, RP-HPLC.
Subscription Login to verify subscription
User
Notifications
Font Size


  • André J Scheen. A review of gliptins in 2011. 2012 Jan; 13(1):81- 99. doi: 10.1517/14656566.2012.642866.Available on pubmed.ncbi.nlm.nih.gov

  • Michael A Nauck , Meier. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions.2016 Jun; 4(6): 525-36.doi: 10.1016/S2213-8587(15)00482-9. Available on.www.diabetes.co.uk/diabetes-medication/dpp-4.

  • www.goodrx.com/gliptins

  • Emilie S Andersen, Carolyn F Deacon, Jens J Holst. Mechanism of action of the DPP-4 inhibitors.2018 Jan; 20(1):34-41. Doi: 10.1111/dom.13018.www.diabetes.org.uk › tablets-and-medication › dpp-4-in

  • Erin E Mulvihill 1 , Daniel J Drucker.Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors:2014 Dec; 35(6): 919-1019doi:10. 1210/er2014-1035 Aailable on www.sciencedirect.com/topics/pharmacology

  • www.medicineindia.org/pharmacology-forgeneric/2797/sitagliptin

  • Ganesh V Sangle, Mohan Patil.Evaluation of pharmacokinetic and pharmacodynamic parameters following single dose of sitagliptin:2018 May; 74(5):561-569.doi: 10.1007/s00228-018- 2433-5.available on www.rxlist.com/januvia-drug clinicalpharmacology/.htm

  • www.healthline.com/health/sitagliptin/oral-tablet

  • En wikipidia.org

  • en.m.wikipedia.org/wiki

  • www.ema.europa.eu/en/documents/scientific

  • Nancy A Thornberry; Baptist Gallwitz. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4):2008 Jul;11(4):512- 32doi: 10.1016/j.beem.2009.03.004available onpubchem.ncbi.nlm.nih.gov/compound/Sitagliptin

  • Rasha M. Ahmed, Ghada M. Hadad, Ahmed E. El-Gendy & Ahmed Ibrahim: Development of HPLC Method for Determination of Sitagliptin in Human Plasma using Fluorescence Detector by Experimental Design Approach.2018; vol.8 (6): 813 – 828.doi: 10.1080/22297928.2018.1545603

  • Balamurugan Krishnan, Kirtimaya Mishra: Quality by Design based Development and Validation of RP-HPLC Method for Simultaneous Estimation of Sitagliptin and Metformin in Bulk and Pharmaceutical Dosage Forms. 2020; vol.10 (4):512-518. doi: 10.5330/ijpi.2020.4.89

  • I. Arulraj, P. Vembu and A. Chenthilnathan: Development and Validation of RP-HPLC Method for the Estimation of Sitagliptin Phosphate in Bulk and Its Tablet Dosage Form. 2016; vol.4 (3):139-143.

  • Sammi Akter, Arghya Prosun Sarkar, Md. Taleb Hossain, Md. Sadikuzzaman, Bidduth Kumar Sarkar, Pijus Saha& Sukalyan Kumar Kundu1 Development and Validation of HPLC Method for Estimation of Sitagliptin in Tablet Dosage Form. 2020

  • Swati D. Bhende, Murali Balaram Varanasi, Konde Abbulu, M. Divya Swetha, V. Shravanthi, J. Karuna Kumari and T. Shayamala RP-HPLC Method for the Simultaneous Estimation of Sitagliptin Phosphate and Metformin Hydrochloride in Combined Tablet Dosage Forms.2012Vol. 28(1):463-469

  • KavithaD, S. K. Sahoo, Venkateswara Rao P., Nagamani M., Bhagyalaxmi:Development and validation of RP HPLC method for determination of metformin and sitagliptin in bulk and pharmaceutical dosage form feb.2017;vol. 5(2):34-39

  • pubchem.ncbi.nlm.nih.gov/compound/Alogliptin

  • aksci.com/item_detail.php?cat=X4993

  • en.wikipedia.org/wiki/Alogliptin

  • pubchem.ncbi.nlm.nih.gov › compound › Alogliptin

  • Hani Naseef, Ramzi Moqadi, and Moammal Qurt: Development and Validation of an HPLC Method for Determination of Antidiabetic Drug Alogliptin Benzoate in Bulk and Tablets. 2018; Vol(18); 1-7.doi:https://doi.org/10.1155/2018/1902510

  • Godge R. K., Shinde G. S, Bhosale M. S:RP-HPLC Method for estimation of Alogliptin and Glibenclamide in Synthetic mixture.2020; vol.13(2):

  • Yadav Priyanka J, Jadhav Sayali S, Mohite S. K.Rajarambapu: development and validation of rp-hplc method for alogliptin benzoate in bulk drug and dosage form.2014; Vol. 1(2): 1-9

  • Vinyas M, Swapna Velivela, Gopi Yadav, Nikunja B Pati, VRM Gupta: Analytical Method Development and Validation of Alogliptin by RP-HPLC Method. 2016; 9(7):775-778. doi:10.5958/0974-360X.2016.00148.7

  • Yogesh Bafana, Yogendra Singh, Gazala Parveen, Mrunal Shirsat, Sampat Naval: Development and Validation of Stability-Indicating RP-HPLC Method for Estimation of Alogliptin and Linagliptin.2018; Vol.9(11): 20196-20216. doi: https://doi.org/10.15520/ijcrr.v9i11.862

  • en.m.wikipedia.org/wiki/Saxagliptin

  • Sohita Dhillon.Saxagliptin A Review in Type 2 Diabetes:2015; Oct 75(15):1783-93. Doi:10.1007/s40265-015-0473-z. Available onpubchem.ncbi.nlm.nih.gov/compound/Onglyza

  • Gaikwad D. D., Patel S. G, Waman S. A, Jadhav S. L, Dhobale S.M: Method Development and Validation of Saxagliptin Hydrochloride by RP-HPLC Method. 2020; Vol.9 (9): 22-28.

  • Bharat G. Murarka, Debarshi Kar Mahapatra, Sandhya M. Bagde, Ujwala N. Mahajan, Ajay G. Pise : Saxagliptin and Metformin Estimation in Tablet Formulation 2020; 10(2):27-36

  • P. B. N. Prasad, K. Satyanaryana, G. Krishnamoha: Development and Validation of a Method for Simultaneous Determination of Metformin and Saxagliptin in a Formulation by RP-HPLC.2015; 6, 841-850. doi: 10.4236/ajac.2015.611080

  • Dr. Pradnya Lokhande:Development and Validation of an HPLC Method for the Analysis of Saxagliptin in Bulk Powder.2020; Vol.4 (2) 2020:37-41.

  • www.selleckchem.com/products/linagliptin-bi-1356.html

  • www.accessdata.fda.gov/drugsatfda_docs/nda/2011/...

  • www.sciencedirect.com/science/article/pii/S

  • en.wikipedia.org/wiki/Linagliptin

  • R. Maruthi, R.S. Chandan, Anand Kumar Tengli: Development and Validation of Stability Indicating RP-HPLC Method for The Estimation of Linagliptin in Active Pharmaceutical Ingredients. 2018; Vol. 7 (1):12-32.

  • Prathyusha Vemula, Dilip Dodda, Uma Mahesh Balekari, Shyam panga, Ciddi Veeresham: Simultaneous determination of linagliptin and metformin by reverse phase-high performance liquid chromatography method: An application in quantitative analysis of pharmaceutical dosage forms. 2015; Vol. 6 | (1):25-28. DOI:10.4103/2231-4040.150368

  • V. sruthi, B. Poornimaa: analytical method development and validation for simultaneous estimation of linagliptin and empagliflozin in bulk and pharmaceutical formulation by RPHPLC. 2019; vol.16 (2):555-568.

  • A.C.K.Prasanna, papain’s, priyanka:method development and validation of linagliptin and metformin by using RP-HPLC in pharmaceutical dosage form.2015;vol.6(1):2673-2678

  • Mahesh Attimarad, Sree Harsha Nagaraja, Bandar E Aldhubaib, Anroop Nair and Venugopala K N: Simultaneous Determination of Metformin and Three Gliptins in Pharmaceutical Formulations Using RP HPLC: Application to Stability Studies on Linagliptin Tablet Formulation.2014; Vol. (4):45-53. DOI: 10.5530/ijper.48.4.7

  • S. Srinivasa Rao, M. Chandra Shekar, and N. Nagaprasanna and T. Supriya: analytical method development and validation of antidiabetic drugs (metformin and linagliptin) in tablet dosage form by using rp-hplc method. 2019; Vol.5(8):113-120

  • Henness S, Keam SJ. Vildagliptin. 2006; 66(15):1989-2001; discussion 2002-4. doi: 10.2165/00003495-200666150-00007. Available onpubchem.ncbi.nlm.nih.gov/compound/Vildagliptin.2006(66)15

  • www.guildlink.com.au/gc/ws/nv/pi.cfm?product=nvpgamor10216

  • www.jocpr.com/articles/formulation-design

  • A. M. Kashida, D. A. Ghorpadea, P. P. Toranmala, and S. C. Dhawale: Development and Validation of Reversed Phase HPLC Method for the Determination of Vildagliptin Using an Experimental Design1.2015; Vol. 70(4): 510–515.doi: 10.1134/S1061934815040061

  • W. Abu Dayyih, M. Hamad, E. Mallah, A. Abu Dayyih, R. Awad, Z. Zakaria and T. Arafat: method development and validation of vildagliptin and metformin hcl in pharmaceutical dosage form by reverse phase–high performance liquid chromatography (RPHPLC) .2018; Vol 10 (1), 36-45. DOI:10.13040/IJPSR.0975- 8232.9(7).2965-72

  • Shrikrishna B. Baokar, Sugandha V. Mulgund Nisharani S. Ranpise: Development and Validation of RP-HPLC Method for Simultaneous Estimation of Vildagliptin and Metformin.2013; 5(2): 95-98.

  • D Raju, P Karunakar, China Babu Jonnakuti and N Asha: Simultaneous estimation of vildagliptin and metformin hydrochloride by using RP-HPLC in bulk and pharmaceutical dosage form. 2019; 8(6): 296-301.


Abstract Views: 507

PDF Views: 0




  • A Review on HPLC Method Development and Validation for Gliptin Class: New Oral Antidiabetic Agents

Abstract Views: 507  |  PDF Views: 0

Authors

Archana B. Gore
PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune-412105, Maharashtra,, India
Manojkumar K. Munde
PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune-412105, Maharashtra,, India
Nikita B. Rukhe
PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune-412105, Maharashtra,, India
Nilesh S. Kulkarni
PES Modern College of Pharmacy (for Ladies), Affiliated to Savitribai Phule Pune University, Moshi, Pune-412105, Maharashtra,, India

Abstract


Gliptin is the class of antidiabetic medicine also called as dipeptidylpeptidase-4. DPP-4 (dipeptidyl peptidase-4) inhibitors (or "gliptins") represent a class of oral anti-hyperglycaemic agents that inhibit the enzyme DPP-4, thus augmenting the biological activity of the "incretin" hormones (glucagon-like peptide-1 [GLP-1] and glucose dependent insulinotropic polypeptide [GIP]) Sitagliptin, Saxagliptin, Alogliptin, Linagliptin, Vildagliptin are the Gliptin class inhibitor for the treatment of type 2 diabetes mellitus and they decrease the breakdown of the incretin hormones such as glucagon like peptide 1 (GLP-1). All together gliptins have a good oral bioavailability which is not significantly influenced by food intake. PK/pharmacodynamics characteristics, that is, sufficiently prolonged half-life and sustained DPP-4 enzyme inactivation, generally allow one single oral administration per day for the management of T2DM; the only exception is vildagliptin for which a twice-daily administration is recommended because of a shorter half-life DPP-4. This paper is an updated review, providing an analysis of both the similarities and differences between the various compounds known as gliptins, currently used in the clinic (sitagliptin, saxagliptin, alogliptin linagliptin and vildagliptin). This paper discusses the pharmacokinetic and pharmacodynamic characteristics of gliptins. In this review we complied analytical method development and determination of the Gliptin inhibitors. Table no.1, 2, 3, 4, 5, shows the analytical method development and validation of Sitagliptin, Saxagliptin, Alogliptin, Linagliptin, and Vildagliptin alone and with its combination by the HPCL method.

Keywords


Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, vildagliptin, Pharmacokinetic parameter, pharmacodynamics parameter, RP-HPLC.

References